IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time-Reference-Cited by-同舟云学术

IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time

Published:2022-10 Issue:5 Volume:49 Page:394-399
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Hoeh Benedikt,Flammia Rocco Simone,Hohenhorst Lukas,Sorce Gabriele,Panunzio Andrea,Tappero Stefano,Tian Zhe,Saad Fred,Gallucci Michele,Briganti Alberto,Terrone Carlo,Shariat Shahrokh F.,Graefen Markus,Tilki Derya,Antonelli Alessandro,Kosiba Marina,Kluth Luis A.,Becker Andreas,Chun Felix K.H.,Karakiewicz Pierre I.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference32 articles.

1. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN Trial;Choueiri;JCO.,2017

2. Alternating treatment with pazopanib and everolimus vs continuous pazopanib to delay disease progression in patients with metastatic clear cell renal cell cancer: the ROPETAR randomized clinical trial;Cirkel;JAMA Oncol,2017

3. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer;Eichelberg;Euro Urol,2015

4. Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial;Hutson;Clin Genitourin Cancer,2017

5. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany;Clinical Genitourinary Cancer;2024-08

2. Volumetric imaging of the tumor microvasculature reflects outcomes and genomic states of clear cell renal cell carcinoma;The Journal of Pathology: Clinical Research;2024-06-26

3. Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results;Clinical Genitourinary Cancer;2024-06

4. Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma;Biomedicines;2024-05-16

5. Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone;Critical Reviews in Oncology/Hematology;2023-08